

# Ketogenic Metabolic Therapy for Neurological Conditions: Hype or Hope? References

## Alzheimer's Disease

- Cunnane SC, Trushina E, Morland C, et al. Brain Energy Rescue: An emerging therapeutic concept for neurodegenerative disorders of ageing. *Nature Reviews Drug Discovery*. 2020;19(9):609-633.
  - Juby AG, Blackburn TE, Mager DR. Use of medium chain triglyceride (MCT) oil in subjects with alzheimer's disease: A randomized, double-blind, placebo-controlled, crossover study, with an open-label extension. *Alzheimer's & Dementia Translational Research & Clinical Interventions*. 2022;8(1).
  - Newport M, VanItallie T, Kashiwaya Y., et al. A new way to produce hyperketonemia: use of ketone ester in a case of Alzheimer's. *Alzheimers Dement*. 2015;11(1):99-103.
  - Phillips MCL, Deprez LM, Mortimer GMN, et al. Randomized crossover trial of a modified ketogenic diet in Alzheimer's disease. *Alzheimer's Research & Therapy*. 2021;13(51).
  - Xu Y, Jiang C, Wu J, et al. Ketogenic diet ameliorates cognitive impairment and neuroinflammation in a mouse model of alzheimer's disease. *Alzheimer's & Dementia Translational Research & Clinical Interventions*. 2022;8(1).
- 

## Multiple Sclerosis

- Achanta LB, Rae CD. Beta-Hydroxybutyrate in the Brain: One Molecule, Multiple Mechanisms. *Neurochemical Research*. 2017;42(1):35-49.
- Brenton JN, Goldman MD. A study of dietary modification: Perceptions and attitudes of patients with multiple sclerosis. *Mult Scler Relat Disord*. 2016 Jul;8:54-57.
- Brenton JN, et al. Pilot study of a ketogenic diet in relapsing-remitting MS. *Neurol Neuroimmunol Neuroinflamm*. 2019;6(4):e565.
- Brenton JN, et al. Phase II study of ketogenic diets in relapsing multiple sclerosis: safety, tolerability, and potential clinical benefits. *J Neurol Neurosurg Psychiatry*. 2022;93(6):637-644.
- Cervenka MC, et al. Establishing an Adult Epilepsy Diet Center: Experience, efficacy and challenges. *Epilepsy & Behavior*. 2016;58:61-8.
- Chenard CA, et al. Nutrient composition comparison between the low saturated fat swank diet for multiple sclerosis and healthy US-style eating pattern. *Nutrients*. 2019;11:616.
- Choi IY, et al. A Diet Mimicking Fasting Promotes Regeneration and Reduces Autoimmunity and Multiple Sclerosis Symptoms. *Cell Rep*. 2016;15(10):2136-2146.
- Dupuis N, et al. Ketogenic diet exhibits anti-inflammatory properties. *Epilepsia*. 2015; 56(7): e95-e98.
- Fitzgerald KC, et al. Diet quality is associated with disability and symptom severity in multiple sclerosis. *Neurol*. 2018;90(1).
- Forbes JD, et al. The Gut Microbiota in Immune-Mediated Inflammatory Diseases. *Frontiers in Microbiology*. 2016;7:1081.

- Kim DY, et al. Inflammation-Mediated Memory Dysfunction and Effects of a Ketogenic Diet in a Murine Model of Multiple Sclerosis. *PLoS ONE*. 2012 05/02;7(5):e35476.
  - Lu Y, et al. Ketogenic diet attenuates oxidative stress and inflammation after spinal cord injury by activating Nrf2 and suppressing the NF-κB signalling pathways. *Neuroscience Letters*. 2018;683:13-18.
  - Milder JB, FAU LL, Patel M. Acute oxidative stress and systemic Nrf2 activation by the ketogenic diet. *Neurobiology of Disease*. 2010;40(1):238-244.
  - Oh U, et al. Serum neurofilament light chain in relapsing multiple sclerosis patients on ketogenic diet. *Mult Scler Relat Disord*. 2023;73:104670.
  - Walton C, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. *Mult Scler*. 2020;26(14):1816-1821.
  - Wetmore E, et al. Ketogenic diet in relapsing multiple sclerosis: patient perceptions, post-trial diet adherence & outcomes. *Clin Nutr*. 2023; 42(8):1427-1435.
  - Woolbright, Koshiya H, Brenton JN. Body size perceptions & diet modification in youth with multiple sclerosis. *Mult Scler Relat Disord*. 2022;58:103402.
  - Youm YH, et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. *Nat Med*. 2015 Mar;21(3):263-269.
- 

### Psychiatric Conditions

- Adams R., et al. Depressive symptoms improve over 2 years of type 2 diabetes treatment via a digital continuous remote care intervention focused on carbohydrate restriction. *J Behav Med*. 2022 Jun;45(3):416-427.
- Adjibade M., et al. Prospective association between ultra-processed food consumption and incident depressive symptoms in the French NutriNet-Santé cohort. *BMC Med*. 2019;17:78.
- Alexander G., et al. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. *Pharmacoepidemiol Drug Saf*. 2011 Feb;20(2):177-84.
- Campbell IH, Campbell H. Ketosis and bipolar disorder: controlled analytic study of online reports. *BJPsych Open*. 2019 Jul 4;5(4):e58.
- Danan A., et al. The Ketogenic Diet for Refractory Mental Illness: A Retrospective Analysis of 31 Inpatients. *Front Psychiatry*. 2022 July; 13:951376.
- Edinoff AN, et al. Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review. *Neurol Int*. 2021 Aug 5;13(3):387-401.
- Firth J., et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. *The Lancet Psychiatry Commission*. 2019; 6(8):675-712.
- Frattarelli D., et al. American Academy of Pediatrics Committee on Drugs. Off-label use of drugs in children. *Pediatrics*. 2014 Mar;133(3):563-7.
- Gómez-Donoso C, et al. Ultra-processed food consumption and the incidence of depression in a Mediterranean cohort: the SUN Project. *Eur J Nutr*. 2020 Apr;59(3):1093-1103.
- Lassale C., et al. Healthy dietary indices and risk of depressive outcomes: a systematic review and meta-analysis of observational studies. *Mol Psychiatry*. 2019; 24:965–986.

- Nasca C., et al. Acetyl-L-carnitine deficiency in patients with major depressive disorder. *Proc Natl Acad Sci USA*. 2018 Aug; 115(34):8627-8632.
- Operto F., et al. The Ketogenic Diet for the Treatment of Mood Disorders in Comorbidity With Epilepsy in Children and Adolescents. *Front Pharmacol*. 2020 Nov 24;11:578396.
- Oudman E., et al. Wernicke Encephalopathy in schizophrenia: a systematic review. *International Journal of Psychiatry in Clinical Practice*. 2021 Aug; 25(3):233-237.
- Rothgeb A., et al. Off-label use information in electronic drug information resources. *J Med Libr Assoc*. 2022 Oct 1;110(4):471-477.
- Touloumis C. The burden and challenge of treatment-resistant depression. *Psychiatriki*. 2021;32:S11-S14.
- Wittich C., et al. Ten common questions (and their answers) about off-label drug use. *Mayo Clin Proc*. 2012 Oct;87(10):982-90.